SYCP2 and ovarian cancer: This discovery of SYCP2’s mechanism in DDR provides novel insight that TKIs can impair transcription-associated homologous recombination repair through ABL1-mediated SYCP2 phosphorylation, thus a potential inhibitory effect on platinum-resistant ovarian cancer cells.